PRMT1 and PRMT8 Regulate Retinoic Acid-Dependent Neuronal Differentiation with Implications to Neuropathology

ZOLTAN SIMANDI,⁎ ERIK CZIPA,⁎ ATTILA HORVATH,⁎ ARON KOSZEGHY,⁎ CSILLA BORDAS,⁎ SZILARD POLUSKA,⁎ ISTVAN JUHASZ,⁎,d LASZLO IMRE,⁎ GABOR SZABO,⁎ BALLY GESSZ,⁎,d ENDRE BARTA,⁎ SASCHA SAUER,⁎ KATALIN KAROLYI,h ILONA KOVACS,h GABOR HÚTÓCZKI,⁎ LASZLÓ BOGNAR,⁎ ALMOS KLEKNER,⁎ PETER SZUCS,⁎,b BALINT L. BALINT,a LASZLO NAGY,a,k,l SASCHA SAUER,g KATALIN KAROLYI,h ILONA KOVACS,h GABOR HÚTÓCZKI,⁎ LASZLÓ BOGNAR,⁎ ALMOS KLEKNER,⁎ PETER SZUCS,⁎,b BALINT L. BALINT,a LASZLO NAGY,a,k,l

Key Words. PRMT1 • PRMT8 • Retinoid signaling • Neural differentiation • Glioblastoma

ABSTRACT

Retinoids are morphogens and have been implicated in cell fate commitment of embryonic stem cells (ESCs) to neurons. Their effects are mediated by RAR and RXR nuclear receptors. However, transcriptional cofactors required for cell and gene-specific retinoid signaling are not known. Here we show that protein arginine methyl transferase (PRMT) 1 and 8 have key roles in determining retinoid regulated gene expression and cellular specification in a multistage neuronal differentiation model of murine ESCs. PRMT1 acts as a selective modulator, providing the cells with a mechanism to reduce the potency of retinoid signals on regulatory “hotspots.” PRMT8 is a retinoid receptor target gene itself and acts as a cell type specific transcriptional coactivator of retinoid signaling at later stages of differentiation. Lack of either of them leads to reduced nuclear arginine methylation, dysregulated neuronal gene expression, and altered neuronal activity. Importantly, depletion of PRMT8 results in altered expression of a distinct set of genes, including markers of gliomagenesis. PRMT8 is almost entirely absent in human glioblastoma tissues. We propose that PRMT1 and PRMT8 serve as a rheostat of retinoid signaling to determine neuronal cell specification in a context-dependent manner and might also be relevant in the development of human brain malignancy.

STEM CELLS 2015;33:726–741

INTRODUCTION

Animal cells in developing embryos receive positional signals from diffusible molecules, called morphogens. Retinoic acid (RA), a natural metabolite of vitamin A, has been proposed to be a vertebrate morphogen [1, 2]. Moleculary, RA acts via the activation of Retinoic Acid Receptor : Retinoid X Receptor (RAR:RXR) heterodimers. RARs and RXRs are two subfamilies of nuclear receptors (NRs) that bind to DNA motifs called RA-response elements (RAREs), typically arranged as direct repeats (DR) and regulate transcription [3]. Unliganded RAR:RXR heterodimers bind to corepressor complexes and are thought to maintain target genes in a repressed state [4]. Ligand binding stimulates a cascade of events resulting in the release of the corepressor complexes, recruitment of transcriptional coactivators, and thus initiation of transcription [5, 6]. However, the composition of coactivator and corepressor complexes is cell-type and context dependent and contributes to cell specification and potentially gene-specific transcription [7].

Members of the protein arginine methyl transferase (PRMT) family have been shown to act as nuclear receptor coactivators [8–11]. Based on their enzyme activity PRMTs are grouped into three groups. Type I enzymes (PRMT1, 2, 3, 4, 6, and 8) catalyze the formation of asymmetric dimethylarginine (aDMA) residues while the type II (PRMT5) enzyme catalyze the formation of symmetric dimethylarginine (sDMA) residues. Both type I and II enzymes generate monomethylarginine (MMA) intermediates. The type III enzyme (PRMT7) only generates a MMA mark [12].

Importantly, asymmetric arginine methylation is associated with cellular differentiation [13, 14]. Early studies revealed high level of aDMA in the nervous system [15], however expression profile of type I PRMTs and their functional contribution to neurogenesis remained largely uncharacterized [16–19].

PRMT1 is a major type of protein arginine methyltransferase and the most studied one [20]. Importantly, PRMT1 null mice die at an early stage, indicating its essential role in embryonic development [17]. PRMT1-dependent
methylation of Arg3 on H4 tail peptides facilitates P300-mediated histone H4 acetylation in vitro [21–23]. These studies collectively suggest that PRMT1 is likely to collaborate with P300 to regulate transcription.

Mechanistically, PRMT1 dimerization/oligomerization or heterodimerization may be required for PRMT1 to achieve its coactivator function [24]. A comparison of mammalian PRMTs revealed that PRMT8 is PRMT1’s closest paralog within this enzyme family, with an identical exon structure and a brain specific expression pattern and can form a heterodimer with PRMT1 [25].

In this work, we explored the mechanistic and functional role of PRMT1 and PRMT8 using a multistage differentiation model of mouse embryonic stem cells (ESCs) to neurons. Our findings implicate asymmetric arginine methylation as a novel way to regulate the potency of retinoic acid regulated transcriptional response. We show that PRMT1 and PRMT8 are linked and act as part of a rheostat to integrate retinoid signaling into neuronal specific gene expression governed by retinoids with implications to neurological disorders.

**Materials and Methods**

Additional details about all of the methods listed below, information about the antibodies used and related citations can be found in the Supporting Information/Extended Experimental Procedures.

**Mouse ESC Culture and Neural Differentiation**

Wild type and genetically modified (see in the text) mouse ESCs (mESCs) (kind gift of Tomo Saric and Istvan Szatmari) were cultured on 0.1% gelatin-coated plates in feeder-free condition in 5% CO2 at 37 °C. Cells were differentiated through embryoid body (EB) formation [26].

**Ligands and Treatment**

Cells were treated with vehicle (dimethylsulfoxide) or with the following ligands: LG268 (a gift from R. Heyman; Ligand Pharmaceuticals, San Diego, CA), RA (Sigma-Aldrich, St. Louis, MO), or AMS80 [27].

**Gene Silencing Assays**

Small hairpin RNA (shRNA) lentiviral plasmids (MISSION shRNA, TRCN0000018490-493 and TRCN0000097479-482) were purchased from Sigma (Sigma-Aldrich, St. Louis, MO) for targeting the mouse PRMT1 and PRMT8, respectively.

**Chromosome Counting**

Cells were treated with colcemid (Sigma-Aldrich, St. Louis, MO) for mitotic arrest and harvested by standard hypotonic treatment and methanol: acetic acid (3:1) fixation. Slides were prepared by standard air-drying method. Twenty DAPI (4', 6 - Diamidino-2-phenylindole) stained chromosomal spreads were counted in each case.

**Teratoma Assay**

mESCs were trypsinized and resuspended in 0.9% normal saline at a concentration of 5 × 10^6 cells per ml. Severe combined immunodeficiency (SCID) mice were anesthetized, and 100 μl of the cell suspension was injected into the lower leg.

After 4–6 weeks, the teratomas were surgically dissected, fixed, embedded in paraffin, and sectioned. The sections were then hematoxylin and eosin stained.

**Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction**

Total RNA was isolated with TRIZOL reagent (Invitrogen, Carlsbad, CA, http://www.invitrogen.com). cDNA synthesis was performed with High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, http://www.appliedbiosystems.com) according to the manufacturer’s recommendation. Quantitative polymerase chain reaction (PCR) was performed using real-time PCR (ABI PRISM 7900, Applied Biosystems). Gene expression was quantified by the comparative C_r method and normalized to Gapdh. Values are expressed as mean ± SD of the mean. GraphPad Prism version 5.02 was used for data interpretation. The sequences of the primers and probes are available upon request.

**Calcium Imaging, Loose-Patch and Whole-Cell Patch-Clamp Recording**

ESCs were differentiated to neurons for 16 days. Whole cell patch clamp and calcium imaging experiments were conducted on these cells to investigate their functional properties. For the measurement of intracellular calcium concentration changes, cells were and loaded with the calcium indicator dye Oregon Green 488 BAPTA-1, AM. Calcium imaging measurements were carried out as described by Koszeghy et al. [28] with minor modifications. Patch clamp experiments were conducted similarly as in Koszeghy et al. [28] with some alterations.

**RNA-seq and Analysis**

RNA-Seq library was prepared from two biological replicates by using TruSeq RNA Sample Preparation Kit (Illumina) according to manufacturer’s protocol. Illumina RNA-sequencing was performed using standard procedures at the Centre National de Genotypage (CNG) Paris, France.

The TopHat-Cufflinks-CummeRbund toolkit trio was used for mapping spliced reads, making transcript assemblies, and getting, sorting, and visualizing gene expression data. Series accession number: SRP042072 / PRJNA248061.

**Microarray Analysis**

Data have been analyzed using GeneSpring v12.6. All microarray data from this study have been submitted to the Gene Expression Omnibus (Series accession number: GSE37060 and GSE37060). Gene lists were imported into IPA (Ingenuity Systems, www.ingenuity.com) to carry out pathway analysis.

**Enrichment of Histone Modification**

Cells were washed and labeled with rabbit anti-H4R3me2a primary antibody diluted ×800 in 1% Bovine Serum Albumin/1×Phosphate Buffer Saline/5 mM EDTA at 4°C overnight using a total volume of 150 μl labeling solution on each slide. Data evaluation and hardware control were performed by the iCys 3.4 software for Windows XP.

**Chromatin Immunoprecipitation and Sequencing**

Chromatin immunoprecipitation (ChiP)-qPCR and ChiP-seq experiments were carried out as previously described [29], with minor modifications. Primary analysis of the ChiP-seq raw reads has been carried out using the ChiP-seq analyze...
Figure 1.

PRMT1 and PRMT8 Regulate Neural Cell Specification
command line pipeline. IGV (Integrative Genomics Viewer) was used for data visualization. All ChIP-seq data from this study have been submitted to the Sequence Read Archive, NCBI (Series accession number: SRP042072/PRJNA248061).

**Tissue Samples**

Glioblastoma and normal brain tissues were collected during neurosurgical operations in the Department of Neurosurgery, University of Debrecen. Normal samples were collected either during functional neurosurgery for epilepsy or nontumor herniated brain tissue during tumor surgery. Sections for histological analysis were cut from the same samples used for mRNA analysis. All procedures were approved by the National Ethical Committee, and every patient signed an informed consent form.

**RESULTS**

**Asymmetric Arginine Methylation Is Present in Distinct Stages of RA-Induced Neural Differentiation**

To explore the involvement of arginine methylation in neuronal development, we set up an ESC-based model system (Fig. 1A). The four stages are: (I) undifferentiated ESCs, (II) aggregates of spontaneously differentiating cells (termed EBs), (III) cells committed to neuroectoderm as a result of all-trans RA treatment, and (IV) the fully differentiated neuronal cells [26]. Importantly, these terminally differentiated neurons have electrophysiological properties similar to those brain-derived neurons and show positive staining for synapsin (Fig. 1B; Supporting Information Fig. S1A), this is in line with the findings of others on ESC derived neurons differentiated using the same method [30].

This model system allows a systematic step-by-step analysis of early cell fate commitment as well as late neural cell type specification. As Supporting Information Figure S1B shows, these stages can be characterized by distinct gene expression signatures. Undifferentiated ESCs express high levels of stem cell specific Oct3/4 [31], while upon induction of spontaneous differentiation the level of Oct3/4 is declining. Treatment with RA causes the activation of RA signaling as it is reflected by the increased Rarβ expression. At this stage, cells become Pax6-positive neural progenitor cells with the characteristics of radial glial cells [26]. Members of the Hox-family, such as Hoxb1, are also induced. In the last stage, high expression of TuJ1 and Dcx, two well-established markers of neurogenesis can be detected [32].

Using this multistage differentiation system, we have found that proteins with sDMA and aDMA residues are present in ESCs (Fig. 1C; Supporting Information Fig. S1C). Asymmetric arginine methylation level of these proteins was changing dynamically during RA-induced neural differentiation, suggesting either an increased level of target proteins or overall type I enzyme activity. A 68-kDa protein (likely Sam68, a previously identified arginine methyltransferase target) [33] showed dramatically increased Asym24 level. Increased expression of Sam68 during neural differentiation could be also detected (Supporting Information Fig. S1C, S1D). Importantly, symmetric arginine methylation was not altered significantly (Fig. 1C; Supporting Information Fig. S1C).

As the next step, we assessed the expression profile of PRMT family members. Gene expression data obtained from RNA-seq in undifferentiated ESCs revealed the high level expression of PRMT1 in undifferentiated cells, suggesting its dominant role in ESCs arginine methylation (Fig. 1D). Reverse transcriptase (RT)-qPCR validation confirmed that PRMT1 is highly expressed in ESCs and its expression remained constant during neural differentiation showing a slight increase upon RA treatment (Fig. 1E). Other type I PRMTs, responsible for aDMA were less abundant in ESCs, but PRMT2, PRMT6, and PRMT8 showed significantly increased gene expression in differentiated neurons. In line with the unaltered sDMA level, expression of type II PRMT5 was not changed (Fig. 1E).

Importantly, we found that asymmetric arginine dimethylation of Histone 4 arginine 3 (H4R3me2a) also indicated increased asymmetric arginine methylation upon differentiation (Fig. 1F). H4R3me2a mark and the identified Sam68 methylation are deposited by PRMT1 and its closest paralog PRMT8 [25, 34], however, their functional redundancy is not understood yet. These results drew our attention to the importance of PRMT1 and PRMT8 in neurogenesis. PRMT1 maintained a more or less even protein level during the...
Figure 2.

PRMT1 and PRMT8 Regulate Neural Cell Specification.

A) D3 and E14 cells were treated with or without shSCR, shPRMT1, or shPRMT8. Western Blot analysis was performed.

B) D3 cells were treated with or without shSCR, shPRMT1, or shPRMT8. Western Blot analysis was performed for PRMT1, ASYM24, OCT3/4, and ACTIN.

C) Western Blot analysis for PRMT1, ASYM24, GAPDH, and NUC in D3 cells treated with or without shSCR, shPRMT1, or shPRMT8.

D) H4R3me2a total amount of histone modification.

E) SSEA-1, Oct3/4, and AP expression in D3, shSCR, shPRMT1, and shPRMT8 treated cells.

F) RNA-seq analysis showing 39 genes upregulated and 126 genes downregulated.

G) WB analysis showing ASYM24 expression in D3, shSCR, shPRMT1, and shPRMT8 treated cells.

H) Motif enrichment analysis for P300 ChIP-seq.

I) P300 normalized read count and distance from the center of consensus P300 peak (bp).

J) Images showing cartilage and pilosebaceous unit.

K) Table showing top canonical pathways and p-values.
course of RA-dependent neural differentiation, while PRMT8 was induced upon RA treatment and was present only in differentiated neurons (Fig. 1G). H4R3me2a and PRMT8 showed nuclear localization, while PRMT1 could also be detected in the cytoplasm of differentiated neurons (Fig. 1H).

PRMT1 Is Responsible for Arginine Methylation in ESCs and Affects Transcription

As a next step we established PRMT1 and PRMT8 knockout ESCs to get functional insights into the role of these two proteins in neurogenesis. Although PRMT1 knockout ESCs were established previously [17], a proper genetic control was not available for comparative studies. Thus, we established PRMT1 and PRMT8 knockout ESCs using shRNA-based gene silencing (Fig. 2A, 2B; Supporting Information Fig. S2A–S2F) in addition to PRMT1 knockout cells (Supporting Information Fig. S2G). Analysis of asymmetrically arginine dimethylated proteins using anti-ASYM24 antibody revealed hypomethylation of certain cellular proteins in PRMT1-depleted ESCs (Fig. 2B; Supporting Information Fig. S2G). PRMT1 was mainly localized in the cytoplasmic fraction, however asymmetric arginine methylation was more abundant in the nucleus (Fig. 2C; Supporting Information Fig. S1C). ASYM24 decorated signal intensity decreased in both fractions as the result of PRMT1 silencing. The total amount of PRMT1 mediated H4R3me2a histone modification was also decreased (Fig. 2D), further demonstrating the functional consequences of the loss of PRMT1 activity and indicating the role of PRMT1 in the regulation of chromatin. PRMT1-depleted or knockout cells showed typical ESC morphology and positive staining for well-established markers of pluripotency (Fig. 2E; Supporting Information Fig. S2H).

To clarify the transcriptional consequences of the reduced level of PRMT1 in ESCs, we carried out global transcriptional analyses using RNA-seq. Pathway analysis clarified that the 165 differentially expressed genes are mainly related to cellular movement (Hspb1, Fgfbp1, Ctgf, Cyr61), proliferation and p53-signaling (Camk2n1, Igfbp3, Smd3, Tpm1), tight junction, and cytoskeletal elements (MvI9, Thbs1, Sepp1) (Fig. 2F; Supporting Information Table 1). A role for PRMT1 in many of these cellular function has been previously suggested in other cellular model systems [35, 36]. Importantly, typical pluripotency markers were not affected by the loss of PRMT1, suggesting that PRMT1 in contrast to CARM1, is not required for the maintenance of pluripotency [14]. Importantly, 39 out of 165 significantly regulated genes showed upregulation in PRMT1-depleted ESCs versus control cells, suggesting the loss of repression on these genes in hypomethylated cells (Fig. 2F). Taken together, data obtained from gene-expression analysis indicate that PRMT1, beside its known transcriptional coactivator function, has a repressive feature on a set of genes, which might be relevant in various cellular functions.

Importance of arginine methylation of coregulators was demonstrated by others [37, 38]. It has been also shown that methylation of Arg3 on H4 tail peptides facilitates P300-mediated histone acetylation in vitro [21–23]. In order to see whether P300 and PRMT1 are present in one complex in ESCs we carried out coimmunoprecipitation experiments. Several asymmetrically arginine methylated proteins were coimmunoprecipitated along with P300 but not with the isotope control (Fig. 2G). Moreover, the asymmetric arginine methylation of these proteins were PRMT1-dependent.

To understand the contribution of PRMT1-mediated arginine methylation in P300-mediated transcriptional and epigenetic program of ESCs we determined the P300 cistrome in the presence and absence of PRMT1. We could identify 3,420 consensus P300 binding sites present in both D3 and E14 control ESCs (Supporting Information). Motif analysis revealed that P300 is mainly recruited to the stem cell specific transcription factor Oct3/4, Sox2, Klf4, Esrrb, and Nanog (Fig. 2H). Considering only those P300 bindings that were detectable and significant in both D3 and E14 cells between control and PRMT1-depleted cells we could identify only approximately 90 genomic regions. Half of these regions showed increased...
Figure 3.

PRMT1 and PRMT8 Regulate Neural Cell Specification

---

©AlphaMed Press 2014

STEM CELLS
P300 occupancy in PRMT1 knockdowns (Fig. 2I). We could identify only few examples where PRMT1-dependent P300 recruitment were coupled to differential gene expression (e.g., lgs21, Ankrd35, Sema3e, Colec12). These results suggest that, at least in undifferentiated ESCs, P300 occupancy is dominantly PRMT1-independent.

We next evaluated the differentiation potential of the PRMT1-depleted cells. Genome-wide comparison and RT-qPCR validation of spontaneously differentiated control and hypomethylated cells showed that classical lineage markers of endoderm, mesoderm, and ectoderm were similarly induced upon spontaneous differentiation (Supporting Information Fig. S3A–S3C). Injection of PRMT1−/− ESCs into immunodeficient mice resulted in teratoma formation with obvious differentiated structures from all three germinal layers, excluding the possibility that residual PRMT1, present in knockdown cells, is sufficient for differentiation (Fig. 2J). PRMT1−/− cells were also able to differentiate to Vimentin− mesenchymal cells and TroponinC also able to differentiate to Vimentin− mesenchymal cells and TroponinC− mesenchymal cells (Fig. 3B). RA, retinoic acid; RAR, Retinoic Acid Receptor; RXR, Retinoid X Receptor; wt, wild-type; veh, vehicle.

To identify differentiation-related signaling pathways that were affected in hypomethylated cells, we compared the gene expression profile at day 4 of differentiation. Pathway analysis based on altered expression of Dusp1, Fox, Smad3, and Tgfβ3 predicted RXR:LXR and RXR:RAR activation as one possible pathway (Fig. 3D). Upon spontaneous differentiation in PRMT1-depleted cells, gene expression changes from control and PRMT1-depleted cells (day 4). 12 hours of RA treatment changed the expression of 127 genes in control cells and 492 genes in hypomethylated cells (Fig. 3A). While most of the known retinoid targets, such as Cyp26a1, Dhrs3, Dlei7, Rbp1, Stra8 were induced to the same degree in PRMT1-depleted and control cells; Hoxa1, Hoxb1, Stra6, Pmp22, and Spsb1 also under RA control [40, 41], showed higher induction in hypomethylated cells (Fig. 3B; Supporting Information Figs. S4, S5A, S5B). Importantly, many genes (e.g., Foxd3, Otx2) showed more pronounced RA-induced repression in PRMT1 knockdown cells, while Zfp428 and Fgfl5 were only repressed in PRMT1-depleted cells (Fig. 3B; Supporting Information Fig. S4). These results suggest a gene-selective regulatory effect of PRMT1 in the RA response of ESCs.

To further investigate the selectivity at the promoter level, we transfected ESCs with the Hoxb1 promoter, containing the DR2 RA-response element, linked to a luciferase reporter gene [41] (Supporting Information Fig. S5C). Transient overexpression of PRMT1 resulted in a decrease in basal transcription level of Hoxb1 (Fig. 3C). To a lesser extent Pmp22 and Spsb1 enhancers were also suppressed in the presence of PRMT1. The ligand induced retinoid response of Hoxb1 and Spsb1 were also decreased (Fig. 3D). Accordingly, in the absence of PRMT1, RA-dependent transcriptional activity was markedly increased (Fig. 3E). Importantly, PRMT1 had no effect in case of a synthetic canonical DR2 response element (Fig. 3F), suggesting a context-dependent and promoter-selective effect of PRMT1 in the regulation of retinoid response.

P300 has been implicated as a regulator of retinoid response in F9 cells [42, 43]. In order to see, whether PRMT1-modulated, RA-induced gene expression correlates with P300 binding, we first determined the RA-dependent P300 cistrome in ESCs. Upon RA treatment there was a three-fold reduction in the number of P300 binding sites in control cells (Fig. 3G) and also the occupancy was substantially decreased (Fig. 3H). We could observe similar P300 redistribution in the PRMT1 knockdown cells (Supporting Information Fig. S6A).

Figure 3. PRMT1 acts as selective regulator of retinoid regulated genes. (A): Proportional Venn-diagram that represents the overlap between gene expression changes in retinoid induced differentiation of control (shSCR) and PRMT1-depleted cells as determined by microarray. EBs at day 4 were treated with 10 μM or 5 μM RA for 12 hours. (B): Gene expression changes from control and PRMT1-depleted cells upon RA treatment. Cells were spontaneously differentiated for 4 days and then treated with RA or vehicle for 12 hours. Fold inductions were calculated from per chip normalized microarray data (vehicle vs. RA treated, n = 3 per condition) for each gene. Calculated values of PRMT1-depleted cells then were normalized by values of the control. Red line shows when the induction is equal in both cell types (e.g., Cyp26a1, Dhrs3). (C): PRMT1-dependent repression of RA-induced enhancers. pcDNA.3.1-PRMT1 (PRMT1) or empty pcDNA3.1 (empty) plasmids were cotransfected with Nfh290-Hoxb1 Luciferase plasmid [41] or Pmp22 and Spsb1 enhancers cloned into Luciferase encoding vector (Supporting Information Fig. S5C). Luciferase signal intensity was determined and normalized to β-gal signal. (D): RA-dependent activation of Hoxb1 promoter and Spsb1 enhancer. Indicated plasmids were cotransfected with Nfh290-Hoxb1-Luciferase or Spbsb1-Luciferase plasmid and cells were treated with RA. (E): Nfh-Hoxb1-Luciferase plasmid was transfected into shSCR or shPRMT1 cells. Cells were treated with RA for 24 hours using the indicated ligand concentration and normalized luciferase values determined. (F): DR2 RA response element containing luciferase plasmid was cotransfected with pcDNA3.1-empty or pcDNA3.1-PRMT1 expression vector. Cells were treated with RA for 24 hours using the indicated concentrations. Normalized luciferase activity was determined and the mean of triplicate determinations ± SD is shown. (G): Area-proportional Venn-diagram of RA induced P300 redistribution. Cistromes of P300 were determined in control (vehicle) and RA-treated (1 μM, 24 hours) D3 shSCR ESCs by ChIP-seq. (H): Histogram of the genome-wide occupancy of common P300 peaks (n = 1,103) in vehicle and RA-treated (1 μM, 24 hours) cells, centralized to common P300 occupied regions. (I): De novo identification of motifs under P300 peaks from ChIP-seq data using Homer. P300 occupied genomic regions were identified in promoter regions of the 398 PRMT1-sensitive RA-regulated genes (A). % of targets refers to the ratio of peaks having the given motif. (J): Genome browser view of the indicated ChIP-seq data on PRMT1-sensitive and PRMT1-insensitive loci. H3K27ac, RXR, and P300 ChIP-seq data were obtained from untreated ESCs and cells treated with 1 μM RA for 24 hours. (K): H4R3me2a ChIP-qPCR signals on the indicated individual enhancers (J) as detected in untreated shSCR, shPRMT1, and shPRMT8 ESCs. (L): P300 ChIP-qPCR signals on the indicated individual enhancers as detected in untreated shSCR, shPRMT1, and shPRMT8 ESCs. (M): RAR, RXR, P300, and Oct3/4 ChIP-qPCR signals on the Hoxa1 enhancer (Fig. 3I) in undifferentiated and RA-treated ESCs. (N): P300 and Oct3/4 ChIP-qPCR signals on the Otx2 enhancer (J) in undifferentiated and RA-treated ESCs. ns, non significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001. Abbreviations: atRA, all-trans Retinoic Acid; ChIP, chromatin immunoprecipitation; DR, direct repeat; EB, embryoid body; Luc, luciferase; PRMT, protein arginine methyl transferase; RA, retinoic acid; RAR, Retinoic Acid Receptor; RAR, Retinoid X Receptor; wt, wild-type; veh, vehicle.
P300 occupancy highly correlates with active enhancers [44]. As a next step, we identified the P300 occupied genomic regions in the close proximity of the 398 PRMT1-sensitive RA regulated genes (Fig. 3A) to identify putative common master regulators of these genes. The motif analysis of these genomic regions revealed binding site enrichment of Oct3/4, Sox2, and Nanog beside the RAR:RXR bound NR half site (Fig. 3I). Interestingly, comparison of promoter regions of PRMT1-insensitive (e.g., Cyp26a1, Dleu7, Rbp1, Stra8, Dhrs3) and PRMT1-sensitive (e.g., Hoxa1, Hoxb1, Spsb1, Pmp22, Stra6 and Foxd3, Otx2, Zfp428, Fgf5) genes showed remarkable differences in the overall binding site enrichment for Oct3/4, Sox2, and Nanog (Fig. 3I). Moreover, P300 redistribution could also only be detected on promoter region of PRMT1-sensitive genes (Fig. 3I; Supporting Information Fig. S6B, S6C), suggesting that P300 and PRMT1 are likely to coregulate such transcriptional “hotspots.”

To get further mechanistic evidence that these regions are targeted by PRMT1, we determined the H4R3me2a signal in the proximity of PRMT1-sensitive and insensitive genes. As shown in Figure 3K and Supporting Information Figure S6D, Hoxa1, Spsb1, Otx2, and Zfp428 enhancers showed clear PRMT1-dependent enrichment of H4R3me2a at these regions, while P300 recruitment was not altered (Fig. 3L; Supporting Information Fig. S6E). RA-dependent changes showed no clear tendency between the compared regions (Supporting Information Fig. S6F, S6G). In accordance with the P300 ChIP-seq data ChIP-qPCR validation confirmed that RA treatment selectively increased the recruitment of P300 to the promoter of Hoxa1 but not to Cyp26a1 or Dhrs3 (Fig. 3M; Supporting Information Fig. S6H).
Spsb1 already showed increased P300 binding which was not further enhanced (Fig. 3J). As expected, Otx2 and Zfp428 showed decreased P300 binding upon RA treatment (Supporting Information Fig. S6H, S6I). Interestingly, we detected a constant Oct3/4 binding on the Hoxa1 enhancer even after 24 hours of RA treatment (Fig. 3M), while Oct3/4 occupancy has significantly decreased on the enhancer of repressed Otx2 (Fig. 3N). These data collectively suggest that RA regulated enhancers can be grouped into two categories, PRMT1 sensitive and insensitive ones with distinct...
transcription factor complexes. The PRMT1 sensitive ones are characterized by PRMT1-dependent H4R3me2a, Oct3/4, Sox2, Klf4, or Nanog (OSKN), and P300 binding.

**PRMT8 Is a RA Inducible Coactivator of Retinoid Signaling**

As it was shown in Figure 1C, RA treatment resulted in changes in asymmetric arginine methylation. Comparison of the expression profile of PRMTs upon short-term RA-induction of day 4 EBs revealed the early upregulation of PRMT8 (Fig. 4A, 4B). To prove that PRMT8 is regulated in a RA-dependent manner, ESCs were treated with RAR and RXR specific ligands. PRMT8 expression could be induced by RAR-specific ligand AM580, but the RXR-specific LG268 had no effect (Supporting Information Fig. S7A). Moreover, RA-dependent induction of PRMT8 showed a similar time- and dose dependence as Hoxb1 and Cyp26a1, well established direct targets of the retinoid signaling pathway (Fig. 4B; Supporting Information Fig. S7B, S7C) [45]. A recently published RAR ChIP-seq in F9 cells [46] allowed us to identify a putative enhancer in the promoter region of PRMT8. This region (−1,400 to −1,450 relative to transcription start site) contains a direct repeat with no spacer (AGGTCAAGGTCA, DR0) that can bind RAR:RXR (Supporting Information Fig. S7D). Transfecting an enhancer trap vector that contains this 300-bp genomic region of the PRMT8 promoter, we could validate functionally the element in response to RA treatment in ESCs (Fig. 4C). These results confirm PRMT8 as a direct RA-regulated gene. Importantly, using the same construct, we could not detect RA-dependent induction of PRMT8 in HEK293T cells (Fig. 4C). This suggests a more complex scenario, where the presence of additional cell-type specific factors are required for proper enhancer activity.

PRMT1 and PRMT8 exhibit high sequence similarities [25], thus we were interested whether loss of PRMT8 may also affect retinoid response. Unexpectedly, loss of PRMT8 had an inhibitory effect on the retinoid response. In a dose-curve comparison of Hoxb1 and Cyp26a1, induction loss of PRMT8 resulted in a significant increase in the half maximal effective concentration (EC50) value of RA (Hoxb1: 4.8 to 860 nM, Cyp26a1: 148 to 808 nM) (Fig. 4D). To validate the coregulatory function of PRMT8 in RAR:RXR signaling, enhancer trap vectors of Hoxb1 or Cyp26a1 RARE were used in a luciferase reporter assay (Supporting Information Fig. S5D). As shown in Figure 4E, ESCs transfected with the reporter alone showed RA-dependent induction, which was further stimulated by cotransfection of PRMT8. In contrast, loss of PRMT8 resulted in a decreased signal intensity (Fig. 4F). Moreover, the decrease observed in PRMT8-depleted cells could be restored by the overexpression of PRMT8 (Supporting Information Fig. S7E). In contrast to PRMT1, loss of PRMT8 also resulted in a decrease in the signal when an artificial canonical DR2 containing reporter was used (Fig. 4G), suggesting that PRMT8 is a general coactivator of RA signaling. To dissect the role of PRMT1 and PRMT8, we used PRMT8-depleted cells on PRMT1−/− background (double knockdown). The inhibitory effect in the absence of PRMT8 was found to be independent of the presence of PRMT1 (Fig. 4H).

**PRMT1 and PRMT8 Regulate Subtype Specification of Differentiating Neural Cells**

Next, we studied if loss of either or both PRMT1 and/or PRMT8 has consequences on RA-inducible neuronal differentiation and/or gene expression. The stability of the knockdowns has been confirmed in differentiated neurons (Fig. 5A; Supporting Information Fig. S8A). Importantly, loss of either PRMT1 or PRMT8 resulted in hypomethylation of neurons as detected by anti-ASYM24 antibody (Fig. 5A).

At day 12 of differentiation, the knockdown derived neural cells showed similar morphology and high expression of neural markers, such as Lhx1, Pax6, or Tuj1 to wild-type cells (Fig. 5B; Supporting Information Fig. S8B). PRMT1 knockout cells could also differentiate to TUJ1+ neurons (Supporting Information Fig. S8C), further demonstrating that PRMT1 is not an essential factor in early neural differentiation. In contrast, genome-wide analysis of day 16 samples revealed dysregulation of several genes in PRMT1- or PRMT8-depleted cells (Fig. 5C). Loss of either PRMT1 or PRMT8 resulted in mainly the downregulation of genes. Interestingly, grouping of the differentially expressed genes identified that a large fraction of the genes (473 out of 2000 measured neurons/condition) were affected neuronal differentiation. (A): Immunoblot analysis of day 16 differentiated neurons derived from the indicated cell types probed for the indicated proteins. (B): TUJ1-staining of day 12 neurons. DAPI costaining was used to visualize cell nuclei. Scale bar, black = 80 µm, white = 40 µm. (C): Heatmap display of microarray gene expression data obtained from D3, shSCR, shPRMT1, and shPRMT8-depleted neurons at day 16, normalized to D3 neurons. Hierarchical cluster analysis is shown. Blue color indicates downregulated, red shows upregulated genes compared to D3-derived neurons. (D): Area-proportional Venn-diagram compares PRMT1-dependent and PRMT8-dependent gene expression changes in differentiated neurons. Cells differentiated for 16 days were used for microarray experiments. Significantly changing genes (FC ≥ 1.5, p < 0.05) were determined by comparing shSCR vs. shPRMT1 or shSCR vs. shPRMT8-depleted neurons. (E): Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) validation of expression level of Phox2b and Gfra2 in the indicated cells. (F): Immunoprecipitation of PRMT1 by full-length FLAG-PRMT8. HEK293T cells were transfected with the indicated constructs. Anti-MYC antibody was used for immunoblot analysis. (G): Mitotic index of day 8 embryoid bodies were evaluated and compared by counting mitotic figures on H&E-stained slides. A representative mitotic figure and a rosettoid structure are shown. Average number of mitotic figures per 20 consecutive HPF (×40 magnification) is shown. (H): Synchronous activity among the cells of the PRMT1 knockdown cultures. Synchronous events labelled with asterisks. Calcium imaging records of six randomly chosen ROIs (regions of interests) per condition are shown. ns, non significant; *, p < 0.05; **, p < 0.01. Abbreviations: HPF, high-power fields; IP, immunoprecipitation; PRMT, protein arginine methyl transferase; WB, Western blot.
947) showed similar dysregulation in both knockdown cell types (Fig. 5D). We validated Phox2b (Paired-Like Homeobox 2b), an important transcription factor of neural specification [47] and Gfra2 (GFDF Family Receptor Alpha), a regulator of neurite outgrowth [48] by RT-qPCR (Fig. 5E). Gene expression data suggested that PRMT1 and PRMT8 might act together in the regulation of these genes. Indeed, as shown in Figure 5F, coimmunoprecipitation studies confirmed that the two proteins are likely present in one complex.

To further evaluate the characteristics of early progenitors and differentiated neurons, we compared the ratio of dividing versus nondividing cells. In the progenitor phase, mitotic index of PRMT1-depleted cells were significantly higher (Fig. 5G). Cell cycle analysis of differentiated cells at day 16 also suggested that PRMT1-depleted cells show significantly higher number of nonterminally differentiated, dividing cells (Fig. 5H).

Importantly, expression level of ESC markers and mesoderm, endoderm, or early ectoderm lineage markers were similarly low in neurons differentiated from hypomethylated cells (Supporting Information Fig. S8D–S8F), further confirming that loss of PRMT1 and PRMT8 do not inhibit the neural differentiation per se. Ingenuity pathway analysis of the 473 genes (Fig. 5D) implicated PRMT1 and PRMT8 in neuronal synaptic formation, glutamate receptor signaling, and axonal guidance (Supporting Information Fig. S8G). Next, we studied functional properties of PRMT1- or 8-depleted neurons by calcium imaging. This method allowed us to compare >200 cells per condition. Importantly, the frequency of calcium peaks and the frequency of action potentials recorded in the same neuron showed a significant correlation (Supporting Information Fig. S9A), in accordance with earlier observations [28, 49, 50]. Approximately 50% of the cells showed neural activity in the control and PRMT8 knockdown cells, while in the PRMT1-depleted cell culture the rate of active cells was almost 100% (Fig. 5I). As a remarkable difference, we found that the frequency of fast calcium signals per active cells was dramatically dropped in PRMT8-knockdowns, suggesting an important role of PRMT8 in the establishment of neuronal excitability (Fig. 5I). Another interesting observation was the frequent occurrence of synchronous activity among the cells of the PRMT1 knockdown cultures (see synchronous events labeled with asterisks in Fig. 5K).

Figure 6. Loss of PRMT8 results in a gene expression profile that resemble neurological disorder. (A): Heatmap visualization of microarray data of the indicated glioma-related markers in ES-derived neurons. Cells differentiated for 16 days were used for microarray experiments, and data were normalized to wild type D3-derived neurons. (B): Gene expression level of Cxcr4 and Dhfr as measured by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in day 16 ESC-derived neurons. (C): Gene expression level of PRMT8 in PRMT1−/− shSCR vs. PRMT1−/− shPRMT8 ESC-derived neurons as measured by RT-qPCR at day 12 of differentiation. (D): Immunoblot analysis of TUJ1 in different stages of PRMT1−/− shSCR vs. PRMT1−/− shPRMT8 neural differentiation. Samples were collected at day 8, 12, and 16. GAPDH serves as a loading control. (E): Gene expression level of indicated genes in PRMT1−/− shSCR vs. PRMT1−/− shPRMT8 ESC-derived neurons as measured by RT-qPCR at day 14 of differentiation. (F): Gene expression level of Cxcr4, Efemp1, PRMT1, and PRMT8 as measured by RT-qPCR. Human normal (n = 54) and glioblastoma multiforme (GBM) (n = 83) samples were compared. Each dot represents an individual sample. (G): Proposed model of PRMT1 and 8’s action on early and late stage of neuronal differentiation. PRMT1 is expressed in early stage, and acts as a selective repressor of retinoic acid induced gene expression. PRMT1-sensitive (e.g., Hoxb1) regions are occupied by Otx2 and Hoxb1, while PRMT1-insensitive sites (e.g., Cyp26a1) are not enriched for these expression factors. P300 is also selectively recruited to the PRMT1-sensitive sites only. H4R3me2a marks can be detected in a PRMT1-dependent manner on the close proximity of all these PRMT1-sensitive enhancers. PRMT1-sensitive, retinoic acid (RA)-repressed genes (e.g., Otx2) also show P300 and OSKN occupancy in untreated ESCs. In the late stage, RA-induced PRMT8 are present in a complex with PRMT1 but PRMT8 might also exist as a homodimer [25]. PRMT8 in such complexes acts as a coactivator that potentiates retinoid response. Hox-genes, Mapt and Phox2b are regulated by both PRMT1 and PRMT8. Pathway analysis predicts REST, MAPT, APP, PSEN1 as upstream regulators responsible for dysregulated gene expression. PRMT8 has a PRMT1-independent regulatory potential as well, affecting gliogenesis-related genes, such as Cxcr4, Dhfr, or Efemp1. ns, non significant; *, p ≤ .05; **, p ≤ .01; ***, p ≤ .001. Abbreviations: ESC, embryonic stem cell; PRMT, protein arginine methyl transferase; RARE, retinoic acid response element.

PRMT8 Regulates Distinct Set of Genes and Loss of PRMT8 Is a Marker of Glioblastoma Multiforme

The gene expression analysis also revealed that several genes, such as Cxcr4, Dhfr, or Efemp1 previously linked to glial differentiation and gliomagenesis [51–53] were expressed differentially only in PRMT8 knockdown cells (Fig. 6A, 6B). Using PRMT1-PRMT8 double knockdown cells, we found that these genes are PRMT8-dependent (Fig. 6C–6E).

We used a large number of human primary glioma samples to confirm that PRMT8-dependent Cxcr4 and Efemp1 indeed show dysregulation in glioblastoma multiforme (GBM) (Fig. 6F). Prompted by this finding and a result of a recent study that linked Single-nucleotide polymorphism (SNP) variation in PRMT8 promoter to familial gliomagenesis [54], we also determined expression of PRMT8 in these samples. Very strikingly, PRMT8 itself showed a substantially lower expression level in GBM samples, while PRMT1 did not show a difference between the groups (Fig. 6F). These data indicate that loss of PRMT8 and genes regulated by it are putative markers in GBM and might participate in its development.

**Discussion**

We combined genetic approaches with genome-wide gene expression technologies to unravel the contribution of PRMT1 and PRMT8 to in vitro neuronal differentiation. We propose the following model (Fig. 6G). There are two distinct phases during the course of neural differentiation: in early stages only PRMT1 is expressed. PRMT1 acts as a selective repressor of a large set of RA-induced genes (Hoxa1, Hoxb1, Pmp22, and Spsb1). The promoter regions of these PRMT1-sensitive genes are regulatory hotspots as they are occupied by OSKN and show P300 recruitment upon RA treatment. Genes, such as Otx2 and Zfp428 that are active in ESCs and occupied by OSKN and P300 are also influenced by PRMT1. This way PRMT1 arms the cells with a negative feedback mechanism to limit RA’s effect on a subset of target genes.

Subsequently, the RA signal directly induces the expression of PRMT8. In this late stage, PRMT8 collaborate with PRMT1 but PRMT8 might also exist as a homodimer [25]. PRMT8 in such complex acts as a coactivator that potentiates...
retinoic response. In this way PRMT1 and its closest paralog PRMT8 integrate the morphogenetic RA signal in a temporal manner acting as a rheostat. Loss of PRMT1 or PRMT8 results in mostly similar changes in neural specification, but PRMT1 and PRMT8 have independent regulatory potential as well.

PRMT1 has been previously identified as a ubiquitously expressed secondary coactivator for nuclear receptors. It has been also shown to bind the activation domain (AD2) of primary coactivators and enhance transcription [10]. In contrast to this, our results now show a repressive function of PRMT1, confirming in principle the findings of previous studies providing evidence for corepressor roles for PRMT1 in different cellular context [55, 56]. These opposing roles in gene expression regulation are not unique to PRMT1, similar phenomena have been reported in case of other coactivators as well [57].

Gene and enhancer selectivity is also a novel and striking feature of PRMT1, however the exact mechanism remains unclear. Strikingly, PRMT1-sensitive sites show characteristics of cell-type specific regulatory hotspots [58]: key transcription factors, such as Oct3/4, Sox2, Klf4, and Nanog appear to be enriched and mark these genomic regions. Importantly, the coactivator P300 is also selectively recruited to these sites upon RA treatment, providing further evidence to the existence of distinct epigenetic states between PRMT1-sensitive and -insensitive sites. We found no indication that loss of PRMT1 would affect P300 recruitment to these hotspots, but we could detect a remarkable decrease in the level of H4R3me2a mark at these sites in PRMT1-depleted cells, suggesting the presence of PRMT1 at these genomic regions. PRMT1-insensitive regions did not show PRMT1-dependent H4R3me2a enrichment, however few exceptions could be noticed (e.g., Rarβ). Due to the lack of reliable ChiP-grade anti-PRMT1 antibody, we could not get reproducible data so far which would provide direct evidence for the presence of PRMT1 at these sites though. A potential mechanism for the enhancer selective effect of PRMT1 is that P300 or a member of this protein complex is arginine methylated and this affects its coactivator function. This scenario would also explain why only P300 recruiting genomic regions are PRMT1-sensitive. Such arginine methylation-dependent regulation of CBP has been demonstrated by others [37, 38], and we also could detect the presence of arginine methylated proteins in the P300 complex. Further studies will be required to evaluate this possibility in neuronal differentiation.

The result of loss of PRMT1 function in differentiating neurons is altered gene expression. Gene expression data obtained can be used in further studies to mechanistically describe the PRMT-dependent transcriptional network in neuregogenesis. Importantly, the detected gene expression differences could be linked to various functional defects. First, we found that loss of PRMT1 resulted in a delay in the cell cycle exit and elevated number of mitotically active cells. These findings are in line with a study which has identified the dominantly PRMT1-mediated H4R3me2a as a marker of postmitotic neurons [59].

A recent study identified methylation of brain sodium channel Nav1.2 in response to seizures [60]. Our preliminary comparison of electrophysiological properties of the knockdown cells led us to the conclusion that PRMT1 and PRMT8 are likely to be responsible for the proper function of ion channels. Further in vitro and animal studies will be required to identify more precisely the functional consequences of loss of these PRMTs.

Dysregulation of RA signaling has also been implicated in disease emergence and progression [61]. It is an intriguing question whether PRMT1 and PRMT8 are involved in pathological conditions of the brain as well. Our pathway analysis indicates a role of PRMT1 and PRMT8 in microtubule-associated protein tau-, amyloid beta A4 protein-, presenilin 1-, and brain-derived neurotrophic factor-related pathways. Moreover, several genes showing dysregulated expression in knockdowns have been also identified in a recent study as potential markers of human AD [62] (Supporting Information Fig. S9B, S9C). As PRMT1 or PRMT8 expression has not been investigated in such disease conditions it is still very tentative to suggest PRMT1 and PRMT8 in the progression of AD. However the observed gene expression pattern calls for further in vivo correlative as well as mechanistic studies.

A previous comparison of mammalian PRMTs revealed that PRMT1 and PRMT8 share the highest degree of identity within this enzyme family [25]. Not only the amino acid sequence of the two proteins but also the intron-exon boundaries are well conserved, suggesting that PRMT8 evolved by the duplication of PRMT1. Importantly, a recent study demonstrated that despite the similarities, PRMT1 and PRMT8 have nonredundant functions in the neural development of Zebrafish [63], suggesting that PRMT8 has acquired novel functions since its duplication. Our genome-wide screen and double knockdown experiments also provide evidence of a PRMT1-independent program of PRMT8.

Dysregulation of RA signaling has been also implicated in progression of different subtypes of cancers [64]. In a recent study, upregulation of PRMT1 has been reported in glioma tissues and glioma cell lines [65]. In order to revisit this issue we used a large patient cohort and found that the RNA levels of PRMT8 are almost completely downregulated in glioma tissues. A trivial explanation may be that PRMT8, a highly specific neural marker, is not expressed in astrocyte-derived tumors [66]. Alternatively, loss of PRMT8 positively affects astrocyte differentiation, resulting in a shift in cell fate commitment. Further in vivo and vitro studies are required to provide evidence to this. Our results show that loss of PRMT8 results in a decrease in the level of Gfra2 and increase in the level of Cxcr4, Dhfr, and Efemp1 in single and double knockdown cells as well. These are established markers of astrocyte-derived glioma [52, 67, 68]. Furthermore, a recent genome-wide linkage study of glioma families linked a PRMT8-related SNP to gliomagenesis [54]. Downstream effect of this SNP has not been linked to the expression of PRMT8 yet. Although further work is required, these results already provide strong support to the notion that PRMT8 might be a genetic risk factor in gliomagenesis and also a putative therapeutic target. Regardless of the mechanism, our results implicate PRMT8 as a biomarker of glioma tissues.

**CONCLUSIONS**

In summary, the results of this study suggest a novel and so far unprecedented mechanism of how two evolutionary linked proteins with similar enzymatic activity can have distinct effects on cellular differentiation through the integration of
retinoid signaling acting as parts of a rheostat. These results provide a new conceptual framework for the interpretation of retinoid signaling in neuronal differentiation and potentially in other tissues as well. These proteins, PRMT1 and PRMT8, can also be targeted pharmacologically to modulate neuronal differentiation in vitro or in vivo and might also be a relevant target in major unresolved clinical issues such as gliomas and Alzheimer’s disease.

ACKNOWLEDGEMENT

We acknowledge Dr. Istvan Szatmari and members of the Nagy laboratory for discussions and comments on the manuscript; Ibolya Furtos, Beata Szalka, Marta Beladi, Imrene Molnar, and Zoltanne Karolyi for technical assistance; Dr. András Dinnyes and Julianna Kobolak (Agricultural Biotechnology Center, Godollo, Hungary) for help with ES work. LN is supported by a grant from the Hungarian Scientific Research Fund (OTKA K100196), TÁMOP422-2012-0023 VÉD-ELEM implemented through the New Hungary Development Plan cofinanced by the European Social Fund and the European Regional Development Fund and Hungarian Brain Research Program—Grant No. KTIA-13-NAP-A-I/9. ZS is a recipient of TÁMOP-422/B10-1/2010-0024 grant and supported by TÁMOP 4.2.4. A/2-11-1-2012-0001/A2-JADJ-13. B.L.B. was supported by a grant from the Hungarian Scientific Research Fund (OTKA F68254). B.L.B. is Bolyai fellow of the HAS, Szodoray fellow of the University of Debrecen Medical and Health Science Center, and recipient of the Magyary Zoltan fellowship supported by the TÁMOP 4.2.4.A/2-11-1-2012-0001 grant. I.J. was supported by a grant from TÁMOP-4.2.2.A-11/1KONV-2012-0023. A.K. was supported by the János Bolyai stipendium and the Hungarian Brain Research Program—Grant No. KTIA_13_NAP-A-V/3. Library preparation and bioinformatic analysis was performed at the Center of Clinical Genomics and Personalized Medicine of the University of Debrecen. RNA-sequencing was performed at the Centre National de Genotypage (CNG) Paris, directed by Jean-Francois Deleuze and supported by the European Sequencing and Genotyping Infrastructure (funded by the European Commission, FP7/2007–2013) under grant agreement no. 26205 (ESGI), as part of the ADIPOMACS transnational access programme.

REFERENCES

14 Wu Q, Bruce AW, Jedrusik A et al. CARM1 is required in embryonic stem cells to maintain pluripotency and resist differentiation. Stem Cells Dev 2009;28:2637–2645.
19 Tsai YJ, Pan H, Hung CM et al. The dominant protein arginine methyltransferase PRMT1 is critical for zebrafish convergence and extension during gastrulation. FEBS J 2011;278:905–917.
of CNS progenitors and neurons from mouse

25 Lee J, Sayegh J, Daniel J et al. PRMT8, a new membrane-bound tissue-specific mem-

26 Bibel M, Richter J, Lacroix E et al. Gen-
eration of a defined and uniform population of
cNS progenitors and neurons from mouse embryonic stem cells. Nat Protoc 2007;2:
1034–1063.

27 Martin B, Bernardon JM, Cavye MT et al. Selective synthetic ligands for human
nuclear retinoic acid receptors. Skin Pharma-

28 Kozhaghy A, Vince J, Rusznak Z et al. Ac-
 Activation of muscarinic receptors increases the ac-
 tivity of the granule neurons of the

29 Barish GD, Yu RT, Karunasisiri MS et al. The

30 Barth L, Sutterlin R, Nenninger M et al. Func-
tional differentiation of stem cell-
derived neurons from different murine back-
grounds. Front Cell Neurosci 2014;8:49.

31 Niwa H, Miyazaki J, Smith AG. Quantita-
tive expression of Oct-3/4 defines differentia-

32 Diez del Corral R, Storey KG. Markers in
vertebrate neurogenesis. Nat Rev Neurosci

33 Cote J, Boisvert FM, Boulanger MC et al. Sa-
m68 RNA binding protein is an in vivo sub-
strate for protein arginine N

34 Sayegh J, Webb K, Cheng D et al. Regu-

35 Boisvert FM, Dery U, Masson JY et al. Ar-
ginine methylation of MR-E11 by PRMT1 is

36 Yu Z, Chen T, Hebert J et al. A mouse
PRMT1 null allele defines an essential role for arginine methylation in genome mainte-

37 Chevillard-Briet M, Trousche D, Vandel L.
Control of CBP co-activating activity by argi-

38 Ceschin DG, Walla M, Wenk SS et al. Methyl-
ynthesis specifies distinct estrogen-

39 Gudas LJ. Retinoic acid methyltransferase 8
TRIP1 in zebrafish embryonic and neural
development is non-redundant with its

40 Dupe V, Davenne M, Brocad J et al. In
vivo functional analysis of the Hoxa-1 3’ reti-
noic acid response element (3’RARE). Devel-

41 Ogura T, Evans RM. Evidence for two
distinct retinoic acid response pathways for

42 Kawasaki H, Eckner R, Yao TP et al. Dis-
tinct roles of the co-activators p300 and CBP
in retinoic acid-induced F9-cell differen-

43 Kashyap V, Gudas LJ. Epigenetic regu-
tory mechanisms distinguish retinoic acid-
mediated transcriptional responses in stem
cells and fibroblasts. J Biol Chem 2010;285:
14534–14548.


45 Simandi Z, Balint BL, Poliska S et al. Ac-
 tivation of retinoic acid receptor signaling
coordinates lineage commitment of sponta-
eneously differentiating mouse embryonic
stem cells in embryoid bodies. FEBS Lett
2010;584:3123–3130.

46 Mendoza-Parra MA, Walla M, Sankar M et al. Dissecting the retinoid-induced differen-
tiation of F9 embryonal stem cells by inte-

47 Brunet JF, Pattyn A. Phox2 genes—From
patterning to connectivity. Curr Opin Genet

48 Yoong LF, Too HP. Glial cell line-derived
neurotrophic factor and neurturin inhibit
neurite outgrowth and activate Rho through
GFR alpha 2, an alternatively spliced iso-
form of GFR alpha 2. J Neurosci 2007;27:
5603–5614.

49 Helmchen F, Imoto K, Sakmann B. Ca2+
buffering and action potential-evoked Ca2+
signaling in dendrites of pyramidal neurons.

50 Stosiek C, Garaschuk O, Holthoff K et al. In
vivo two-photon calcium imaging of neu-
ronal networks. Proc Natl Acad Sci USA
2003;100:7319–7324.

51 Ehtesham M, Thompson RC. CXCR4-
form of GFR alpha 2. J Neurosci 2007;27:
1157.

52 Iidaiba A, Carvalho Silva R, Ciniere I et al. Genomic
changes in progression of low-grade gliomas. J Neurooncol 2008;90:
133–140.

53 Huang J, Vogel G, Yu Z et al. Type II argi-
nine methyltransferase PRMT5 regulates
gene expression of inhibitors of differen-
tiation/DNA binding Id2 and Id4 during glial cell
44432.

54 Liu Y, Melin BS, Rajaraman P et al. Insight in glioma susceptibility through an
analysis of 6p22.3, 12p13.33-12.1, 17q22–
23.2 and 18q23 SNP genotypes in familial
and non-familial glioma. Hum Genet 2012;
131:1507–1517.

55 KleinSchmidt MA, Streubel G, Samans B et al. The protein arginine methyltransferases
CARM1 and PRMT1 cooperate in gene regu-

56 Lafleur VN, Richard S, Richard DE. Trans-
criptional repression of hypoxia-inducible
factor-1 (HIF-1) by the protein arginine meth-
ethyltransferase PRMT1. Mol Biol Cell 2014;25:
925–935.

57 Rogatsky I, Luecke HF, Leitman DC et al. Alter-
native surfaces of transcriptional coregula-
tor GRIP1 function in different glucocorticoid
receptor activation and repression contexts. Proc Natl Acad Sci USA 2002;99:16701–
16706.

58 Siersbaek R, Nielsen R, John S et al. Exten-
sive chromatin remodelling and estab-
lishment of transcription factor ‘hotspots’
during early adiogenesis. EMBO J 2011;30:
1459–1472.

59 Chitika A. Dynamic distribution of his-
tone H4 arginine 3 methylation marks in the
developing murine cortex. PLoS One 2010;5:
e13807.

60 Baek JH, Rubinstein M, Scheuer T et al. Re-
ciproc changes in phosphorylation and
methylation of mammalian brain sodium
channels in response to seizures. J Biol Chem

61 Lee HP, Casadesus G, Zhu X et al. All-
trans retinoic acid as a novel therapeutic

62 Miller JA, Woltjer RL, Goodenour JM et al. Genes and pathways underlying
regional and cell type changes in Alzheimer’s

63 Lin YL, Tsai YJ, Liu YF et al. The critical
role of protein arginine methyltransferase
PRMT6 in Zebrafish embryonic and neural
development is non-redundant with its

64 Ali R, Campos B, Dyckhoff G et al. Quan-
tification of retinoid concentrations in human
serum and brain tumor tissues. Anal Chim

65 Wang S, Tan X, Yang B et al. The role of
protein arginine-methyltransferase 3 in gli-

66 Kosuaka A, Mori Y, Koyama Y et al. The distribution and characterization of endoge-
nous protein arginine N-methyltransferase 8
in mouse CNS. Neuroscience 2009;163:1146–
1157.

67 Hu B, Thirumara-Rajamani KK, Sim H et al. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell
motility and invasion. Mol Cancer Res 2009;
7:1756–1770.

68 do Carmo A, Patricio I, Cruz MT et al. CCX12/CXCR4 promotes motility and prolif-
eration of glioma cells. Cancer Biol Ther

See www.StemCells.com for supporting information available online.